MAB10753
抗半胱天冬酶3（活性形式）抗体，克隆3D9.3
clone 3D9.3, from mouse
别名:
Caspase-3, CASP-3, Apopain, Cysteine protease CPP32, CPP-32, Protein Yama, SREBP cleavage activity 1, SCA-1, Caspase-3 subunit p17, Caspase-3 subunit p12
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
3D9.3, monoclonal
Application:
flow cytometry
immunocytochemistry
western blot
immunocytochemistry
western blot
Species reactivity:
human
Citations:
7
Technique(s):
flow cytometry: suitable
immunocytochemistry: suitable
western blot: suitable
immunocytochemistry: suitable
western blot: suitable
Uniprot accession no.:
产品名称
抗半胱天冬酶3（活性形式）抗体，克隆3D9.3, clone 3D9.3, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
3D9.3, monoclonal
species reactivity
human
technique(s)
flow cytometry: suitable
immunocytochemistry: suitable
western blot: suitable
isotype
IgMκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... CASP3(836)
Analysis Note
通过蛋白质印迹在HeLa 细胞裂解物中的进行了评估。
蛋白质印迹分析：0.1µ g/mL该抗体可在10µ g HeLa和星形孢菌素处理的HeLa细胞裂解物中检出胱天蛋白酶3（活性形式）。
蛋白质印迹分析：0.1µ g/mL该抗体可在10µ g HeLa和星形孢菌素处理的HeLa细胞裂解物中检出胱天蛋白酶3（活性形式）。
Application
免疫细胞化学分析：代表性批次的1：500稀释液在Hela和Hela/星形孢菌素3小时细胞中检测到胱天蛋白酶3（活性形式）。
流式细胞术分析：代表性批次的1：400稀释液在Jurkat T细胞中检测到胱天蛋白酶3（活性形式）。
流式细胞术分析：代表性批次的1：400稀释液在Jurkat T细胞中检测到胱天蛋白酶3（活性形式）。
抗胱天蛋白酶3（活性形式），克隆3D9.3是一种靶向胱天蛋白酶3（活性形式）蛋白的抗体，经验证可用于WB、ICC&流。
Biochem/physiol Actions
该抗体显示出对裂解的17 kDa活性形式的特异性，但不与35 kDa的非活性（原）形式的胱天蛋白酶3发生交叉反应。
General description
胱天蛋白酶-3（CPP32，Apopain）是研究最广泛的凋亡蛋白。胱天蛋白酶-3被合成为一种无活性的酶（32 kDa），该酶在经历凋亡的细胞中通过自身蛋白水解和/或被另一种上游蛋白酶切割而处理。胱天蛋白酶-3的加工形式由大（17 kDa）和小（12 kDa）亚基组成，它们结合形成活性酶。活性胱天蛋白酶-3蛋白水解切割并激活其他胱天蛋白酶，以及细胞中的相关靶标，例如PARP和DFF。
观测值〜17 kDa。胱天蛋白酶3在凋亡过程中裂解为17 kDa和12 kDa活性形式。
Immunogen
对应于人胱天蛋白酶3（活性形式）的KLH偶联线性肽。
Other Notes
替代品：04-1090；04-439
浓度：请参考批次特异性浓缩物的分析证书。
Physical form
形式：纯化
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Axel H Schönthal et al.
Cancers, 13(14) (2021-07-25)
Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination with
Catalina Silva-Hirschberg et al.
Therapeutic advances in medical oncology, 11, 1758835919891567-1758835919891567 (2019-12-17)
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of primary cutaneous lymphomas and represent complex diseases regarding their physiopathology and management. Depending on the stage of the disease, different treatment regimens are applied, but there is no consensus on
Erdal Erkoç et al.
Turkish archives of otorhinolaryngology, 61(3), 124-133 (2023-11-29)
To investigate the effects of cross-linked hyaluronic acid (CLHA) in an experimental model of vestibulotoxicity and cochleotoxicity. Twenty-eight female Wistar albino rats (200-250 g) were divided into four groups. Group A received 0.06 mL of 13.33 mg/mL gentamicin, Group B
John Chun-Hao Chen et al.
Oncology letters, 17(1), 638-645 (2019-01-19)
Trichostatin A (TSA), a hydroxamate histone deacetylase inhibitor, is a compound that has been identified to induce anticancer activity. The aim of the present study was to investigate whether sorafenib, in combination with TSA, was able to augment the anticancer
Ya-Jing Zhang et al.
Toxicology research, 10(5), 1052-1063 (2021-11-05)
Cancer is one of the leading causes of death in the world. It is very important to find drugs with high efficiency, low toxicity, and low side effects for the treatment of cancer. Flavonoids and their derivatives with broad biological
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持